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Abstract Background: Although oseltamivir is a common influenza treatment, there is a lack of data on the economic benefits of
timely oseltamivir treatment.
Methods: From February 2004 through June 2007, 116 hospitalized children ≤15 years of age with laboratory-
confirmed influenza who received oseltamivir were identified via retrospective medical chart review. Demographic,
clinical, and cost data were abstracted and multivariate linear regression was used to assess the association between
oseltamivir time to treatment and treatment-related costs among hospitalized children with laboratory-confirmed
influenza.
Results: Overall, 28% (n = 33) of patients were treated with oseltamivir ≥day 3 of admission. Rapid influenza diagnostic
test was used in a significantly lower proportion of patients treated with oseltamivir ≥day 3 of admission compared with
those who received oseltamivir earlier. On multivariate linear regression, initiation of oseltamivir ≥day 3 of admission
was associated with a 60.84% increase (95%CI: 32.59–95.11) in treatment-related hospital costs, compared with
initiation on admission.
Conclusion: Delayed initiation of oseltamivir was found to be associated with increased treatment-related hospital costs
among children hospitalized with laboratory-confirmed influenza.
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Influenza viruses cause acute respiratory illness in all ages, and
both pandemic and seasonal influenza can lead to excessive res-
piratory disease-associated hospitalization, mortality, and eco-
nomic impact.1–3 Children, especially if they are younger or have
underlying medical conditions, often experience a greater influ-
enza burden.4–6 Pediatric influenza results in substantial morbid-
ity, direct and indirect costs, and excess health-care utilization.7–9
Furthermore, children can cause secondary illness in the family
by transmitting the influenza virus to other household
members.9,10
Hospitalization with respiratory illness is especially common
among younger Korean children during influenza (or other res-
piratory virus) season given that South Korea’s mandatory
national insurance system covers a large portion of medical
charges incurred during hospitalization. In the USA, a recent
study reported the mean cost of influenza-associated hospi-
talization, as estimated at $US 13 159, and the annual
national direct medical cost due to seasonal influenza at $US
10.4bn.1,8
Neuraminidase inhibitors are reported to be therapeutically
effective and to reduce influenza-associated illness duration,
severity, complication risk, influenza-related mortality, and even
antibiotic use.11–15 Oseltamivir is a commonly used antiviral
agent, and notably, in the January 2011 issue of the U.S. Centers
for Disease Control and Prevention’s Morbidity and Mortality
Weekly Report, oseltamivir was recommended for use in patients
hospitalized with suspected or confirmed influenza.16 It is FDA-
approved as influenza treatment for persons aged ≥2 weeks and is
recommended to be given within 2 days of symptom onset. Given
the year-to-year variation in influenza activity and growing
global concern for viral resistance to oseltamivir, the recommen-
dation and treatment guidelines are updated regularly based on
influenza surveillance data.16–18
The burden of influenza, however, remains high, and in Korea,
up to 20% of viral respiratory disease hospitalizations were
reported to be due to influenza virus infection despite the national
influenza vaccination coverage rate being close to 40%.19,20
Although oseltamivir is a common influenza treatment, there is
no standard treatment regimen for seasonal influenza control in
Korea. Although it is well-documented in previous literature that
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the prompt initiation of oseltamivir is associated with better clini-
cal outcome,21–24 there are no studies estimating the economic
impact of earlier initiation of oseltamivir in influenza treatment.
To help fill the knowledge gaps, we investigated whether there is
an economic benefit by evaluating the association of time to
oseltamivir treatment with treatment-related hospital cost among
hospitalized children with laboratory-confirmed influenza in
Korea.
Methods
Nasal aspirate specimens were systematically collected from
patients presenting with acute respiratory symptoms at Ansan,
Anam, and Guro Hospitals, affiliated with Korea University
(KU). These hospitals serve the communities of Ansan city, a
neighboring city of Seoul, and the districts of Guro and Anam in
Seoul. Nasal aspirate specimens were routinely tested to identify
adenovirus, parainfluenza, respiratory syncytial virus (RSV), and
influenza A/B on viral culture, using three standard cell lines
(HEp-2, MDCK and LLC-MK2). Given that results from viral
culture test may take up to 5 days, a subset of patients with
clinically suspected influenza was tested for influenza using rapid
influenza diagnostic text (RIDT; Directigen EZ Flu A + B Test
Kit; Becton-Dickinson, Franklin Lakes, NJ, USA).
At three KU hospitals, 2781 patients who presented with
respiratory symptoms were tested for influenza virus, and 1232
hospitalized patients and outpatients were found to have
laboratory-confirmed influenza virus. The analysis was limited to
hospitalized patients because it was based on treatment prescrip-
tion information. Among hospitalized children ≤15 years of age
with laboratory-confirmed influenza who initially presented with
respiratory symptoms at one of the KU hospitals from February
2004 through June 2007, we excluded children with: (i) concur-
rent respiratory infection with one or more viruses (RSV,
parainfluenza virus, or adenovirus); (ii) nosocomial influenza
episodes with virus detection ≥7 days after admission; or (iii)
recurrent infection returning to hospital within 2 weeks of dis-
charge with the same virus type. Because the analysis was of the
association between time to treatment with oseltamivir and hos-
pital costs, the final study group consisted of 116 inpatients
treated with oseltamivir during their hospital stay (Fig. 1).
We conducted a retrospective review of medical records for
these hospitalized patients with laboratory-confirmed influenza
who were treated with oseltamivir. We abstracted the following
demographic and clinical data from patient medical records in
the KU hospital electronic database: influenza virus type, dates
of admission and discharge, diagnosis, signs and symptoms,
body temperature, duration of fever, medical history, pre-
existing medical conditions, vital signs, hematologic and
radiologic test results, and treatment information. Direct hospi-
tal medical costs were obtained from the hospital billing/
registry office. Study approval was obtained from the
Institutional Review Boards of the KU Ansan Hospital and the
International Vaccine Institute.
Fig. 1 Patient selection.
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Variable for analysis
Time to treatment (in days) was calculated from date of admis-
sion to the first oseltamivir (Tamiflu®; Roche Pharmaceuticals,
Basel, Switzerland) treatment among hospitalized patients pre-
senting with respiratory symptoms. Time to treatment was meas-
ured from admission rather than from onset of fever to avoid
possible unreliable reporting of the clinical evolution of the
disease by caregivers. Initially derived to reflect the recom-
mended time window for oseltamivir treatment in the hospital
setting, the variable constructed allowed reporting on the eco-
nomic benefit of initiating oseltamivir treatment within 2 days of
hospitalization, and was more evidence based and definitive than
measuring 2 days from onset of symptoms. Also, there was
variation in how the attending physicians measured fever dura-
tion: one would count by days while another would count by
hours, considering 24 h as 1 day.
Patients were categorized into those given oseltamivir on
day 1 of admission, day 2 of admission, and ≥day 3 following
admission (outside the recommended 2 day window after onset
of symptoms). The patients who receive oseltamivir later in
their admission are likely to have the duration of hospitalization
extended, at least, by the number of days of the delay. To avoid
increase in total hospital cost among these patients due to pro-
longed hospital stay, we selected treatment-related cost as the
outcome of analysis, rather than the total hospital costs which
also include test cost, admission-related fees, and treatment
costs. Treatment-related cost, consisting of charges for injec-
tion, medication, treatment materials, physiotherapy, surgery,
anesthesia, and blood infusion, as applicable, would reflect the
economic burden due to delayed onset of oseltamivir regardless
of changes in the costs due to extension of the duration of hos-
pitalization.
Medical charges were converted from Korean won currency
(KRW) to US dollars with the 2004–2007 average exchange rate.
Because treatment-related charges had a non-normal distribution
(mean, $US115; median, $US105; range, $US24–360), on
univariate analysis, we used log-transformed treatment-related
charges as the outcome for the linear regression model. The
estimates on the natural log scale were back-transformed.
Diagnosis at admission was categorized by primary clinical
manifestation. Primary admission diagnoses of pneumonia, bron-
chitis, croup, and asthma were grouped as lower respiratory tract
illness (LRTI), while acute pharyngitis, sinusitis, and laryngitis
were grouped as upper respiratory illness. Urinary tract infection,
sepsis, and neurologic (e.g. convulsions, febrile seizure,
Guillain–Barré syndrome), gastrointestinal (e.g. diarrhea, acute
gastroenteritis, stomatitis), and cardiovascular-related conditions
were grouped as “non-respiratory” diseases. Axillary tempera-
ture ≥37.5°C was defined as fever. The median of the highest
temperature recorded during hospitalization, 38.8°C, was used as
the cut-off to create a dichotomous variable indicating elevated
body temperature. Complications occurring during hospital stay
were secondary bacterial pneumonia, other secondary bacterial
infection, encephalitis, neurologic problems, exacerbation of pre-
existing medical conditions, and so on.
Statistical analysis
A sample of 116 patients hospitalized with community-acquired,
laboratory-confirmed influenza treated with oseltamivir was used
to examine the relationship between oseltamivir time to treatment
from admission and treatment-related cost in the hospital setting.
For continuous variables, ANOVA was performed and categori-
cal comparisons were made using chi-squared and Fisher’s exact
tests with significance at P < 0.05. To identify the pattern of
geometric mean hospital charges in relation to day of onset of
oseltamivir treatment, we used trend tests to identify any signifi-
cant patterns in the β. Bivariate analysis was used to identify
potential confounders and covariates of interest for the regression
model, using SAS® version 9.0 (SAS Institute, Cary, NC, USA),
and Stat/Transfer 8® (Circle Systems, Seattle, WA, USA).
To adjust for variability in clinical indicators of influenza that
may have prompted earlier initiation of oseltamivir, clinical
parameters were analyzed as markers of initial illness condition
and were included in multivariate analysis. The following param-
eters were included: temperature measured at admission, selected
signs and symptoms, admission diagnosis, previous influenza
infection in the past year, influenza circulating season, and pres-
ence of underlying disease. Additional clinical characteristics
such as laboratory and diagnostic test results, concurrent antibi-
otic therapy, fever duration, and complications during hospitali-
zation were included as potential confounders to minimize the
influence they may have on treatment-related decisions and,
hence, on clinical course. Linear regression was performed with
the outcome as the log-transformed, treatment-associated hospi-
tal costs and the main predictor as oseltamivir time to treatment
calculated from admission. The β, percent change in treatment-
related costs, and 95%CI, are reported.
Results
Patient characteristics
Among the 116 community-acquired influenza hospitalizations
identified, 53% (n = 62) and 18% (n = 21) were treated with
oseltamivir on days 1 and 2 of admission, respectively. Although
all study participants underwent testing to confirm influenza on the
same day that they were admitted to hospital with respiratory signs
and symptoms, 28% (n = 33) were given oseltamivir >2 days after
admission, that is, outside the recommended 2 day window after
the onset of symptoms. Overall, 74% of the 116 oseltamivir-
treated patients were ≤5 years of age (n = 86; Table 1).
Clinical characteristics
Among the 116 patients, the mean length of hospital stay signifi-
cantly increased as the oseltamivir time to treatment increased
(P < 0.001; Table 2). Additionally, the mean peak body tempera-
ture also increased as the oseltamivir time to treatment increased
(P = 0.032). Patients whose oseltamivir therapy began ≥3 days of
admission were less likely to undergo influenza antigen detection
tests (33% vs 64% and 76% for day 1 and day 2, respectively) and
were more likely to receive combined therapy with antibiotics
(91% vs 65% and 81% for day 1 and day 2, respectively), com-
pared to those who received oseltamivir from day 1 or day 2 of
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admission. Distribution of episodes by season was significantly
different across the oseltamivir time-to-treatment groups, in that
patients who received oseltamivir within 2 days of admission
were more likely to have influenza viral infection in winter (71%
for both groups given oseltamivir on days 1 and 2 of admission),
while 55% of the patients given oseltamivir ≥day 3 of admission
had influenza hospitalization in spring.
On average, the mean duration from onset of fever to admis-
sion was 2.73 days for patients given oseltamivir on day 1 of
admission. For those patients treated with oseltamivir on day 2 of
admission, the mean duration between fever onset and admission
was 1.85 days. For the patients treated with oseltamivir ≥day 3
following admission, the mean interval between fever onset and
admission was 2.33 days. There was no statistically significant
difference in the period from onset of fever to admission between
those treated with oseltamivir within 2 days and those treated
≥day 3 following admission (P = 0.378).
Treatment-related hospital costs
The mean total hospital costs and treatment-related costs of the
116 laboratory-confirmed patients treated with oseltamivir during
hospitalization increased as the oseltamivir time to treatment
Table 1 Patient characteristics vs oseltamivir time to treatment
Oseltamivir time
to treatment
n Age (years)
Mean ± SD
Female
n (%)
Influenza virus type, n (%) Clinical impression on admission, n (%)
A B Unidentified LRTI URI Non-respiratory
Day 1 of
hospitalization
62 3.81 ± 3.64 30 (48.4) 39 (62.9) 12 (19.4) 11 (17.7) 17 (27.4) 31 (50.0) 14 (22.6)
Day 2 21 2.40 ± 2.07 4 (19.0) 9 (42.9) 4 (19.0) 8 (38.1) 11 (52.4) 5 (23.8) 5 (23.8)
≥Day 3 33 4.05 ± 2.69 19 (57.6) 17 (51.5) 13 (39.4) 3 (9.1) 16 (48.5) 13 (39.4) 4 (12.1)
Total 116 3.59 ± 3.18 53 (45.7) 65 (56.0) 29 (25.0) 22 (18.9) 44 (37.9) 49 (42.2) 23 (19.8)
LRTI, lower respiratory tract illness; URI, upper respiratory illness.
Table 2 Hospitalization and symptoms vs oseltamivir time to treatment
Characteristics Oseltamivir time to treatment (days) Total (n = 116) P
Day 1 of
hospitalization
(n = 62)
Day 2
(n = 21)
≥Day 3
(n = 33)
Length of hospital stay (days), mean ± SD 3.32 ± 1.48 4.43 ± 2.31 5.70 ± 2.66 4.17 ± 2.26 <0.001
Fever duration (days), mean ± SD 4.40 ± 2.50 3.50 ± 1.88 5.03 ± 2.51 4.42 ± 2.45 0.084
Temperature on admission (°C), mean ± SD 37.71 ± 0.85 37.80 ± 0.74 37.78 ± 1.08 37.77 ± 0.92 0.949
Peak temperature during hospitalization (°C), mean ± SD 38.61 ± 0.80 38.99 ± 0.99 39.22 ± 0.74 38.91 ± 0.85 0.032
Symptoms, n (%)
Cough 54 (88.5) 16 (76.2) 26 (78.8) 96 (83.5) 0.169
Expectoration 31 (50.8) 11 (52.4) 15 (45.5) 57 (49.6) 0.615
Rhinorrhea 38 (62.3) 10 (47.6) 14 (42.4) 62 (53.9) 0.045
Chills 6 (9.8) 2 (9.5) 4 (12.1) 12 (10.4) 0.736
Headache 4 (6.6) 0 1 (3.0) 5 (4.4) 0.285
Diarrhea 1 (1.6) 4 (19.1) 3 (9.1) 8 (7.0) 0.134
Sore throat 2 (3.3) 0 5 (15.2) 7 (6.1) 0.032
Signs, n (%)
Pharyngitis 49 (80.3) 16 (76.2) 30 (90.9) 95 (82.6) 0.333
Rales or wheezing 11 (18.0) 9 (42.9) 12 (36.4) 32 (27.8) 0.030
Injected tympanic membrane 6 (9.8) 2 (9.5) 5 (15.2) 13 (11.3) 0.457
Rhonchi 3 (4.9) 0 3 (9.1) 6 (5.2) 0.479
Season, n (%) 0.024
Spring (March–May) 18 (29.5) 6 (28.6) 18 (54.6) 42 (36.5)
Winter (December–February) 43 (70.5) 15 (71.4) 15 (45.5) 73 (63.5)
No previous influenza infection in the same year
(vs unknown), n (%)
25 (41.0) 9 (42.9) 19 (57.6) 53 (46.1) 0.182
Pre-existing conditions, n (%) 3 (4.9) 1 (4.8) 4 (12.1) 8 (7.0) 0.209
Complications during hospitalization, n (%) 5 (8.2) 1 (4.8) 3 (9.1) 9 (7.8) 0.961
Infiltrate on chest radiograph, n (%) 8 (12.9) 6 (28.6) 7 (21.2) 21 (18.1) 0.225
RIDT, n (%) 39 (63.9) 16 (76.2) 11 (33.3) 66 (57.4) 0.022
Antibiotics during hospitalization, n (%) 40 (64.5) 17 (81.0) 30 (90.9) 87 (75.0) 0.005
White blood cell count, n (%) 0.152
Normal 43 (70.5) 18 (85.7) 27 (81.8) 88 (76.5)
Abnormal 18 (29.5) 3 (14.3) 6 (18.2) 27 (23.5)
RIDT, rapid influenza diagnostic test. The bold data showed that the value is under 0.05.
396 JK Lim et al.
© 2014 Japan Pediatric Society
lengthened (both P < 0.001; Table 3). Linear regression analysis
was done with treatment-related hospital costs as the outcome
and time to oseltamivir treatment as the primary predictor. On
unadjusted linear regression, a 98.95% (95%CI: 61.46–145.15)
increase in treatment-related hospital costs was associated with
initiation of oseltamivir ≥day 3 of admission compared to initia-
tion on the day of admission (β = 0.687, P < 0.001). On multi-
variate linear regression, adjusting for potential confounders, a
60.84% (95%CI: 32.59–95.11) increase in treatment-related hos-
pital costs was associated with oseltamivir initiated ≥day 3 of
admission (β = 0.475, P < 0.001), compared to initiation on day
1 (Table 4). No significant difference was found between those
with oseltamivir initiation on days 1 and 2 of hospitalization.
Antibiotic therapy with oseltamivir was associated with a
50.97% (95%CI: 24.74–82.72) increase in treatment-associated
hospital costs compared to oseltamivir monotherapy. Conversely,
oseltamivir-treated patients with non-respiratory diagnosis at
admission were associated with a 43.15% (95%CI: −56.84 to
−25.13) decrease in treatment-related hospital costs compared to
those diagnosed with LRTI.
Discussion
Using a sample of children with laboratory-confirmed influenza
and presenting with respiratory symptoms on admission, we
identified a significantly higher treatment-related hospital cost,
increased by 60%, associated with oseltamivir treatment on day 3
of admission or thereafter, compared to oseltamivir given on the
day of admission. There was no significant difference in
treatment-related hospital costs between those treated with
oseltamivir on days 1 and 2 of admission. Although half of the
present sample of laboratory-confirmed, community-acquired
influenza patients was treated with oseltamivir on the day of
admission, one-third was given oseltamivir on day 3 of admission
or later, outside the recommended 2 day window after the onset
of symptoms. Patients whose oseltamivir therapy was initiated
after day 3 of admission were half as likely to undergo RIDT and
Table 3 Time to treatment vs hospital costs
Hospital day of
oseltamivir treatment
No. patients Hospital costs ($US), mean ± SD
Treatment-related***† Hospital admission***† Testing(n.s.)† Total***†
Day 1 62 112.76 ± 1.61 246.63 ± 1.66 302.91 ± 1.59 758.87 ± 1.44
Day 2 21 139.26 ± 1.69 331.52 ± 1.91 276.58 ± 1.35 859.07 ± 1.40
Day 3 11 179.28 ± 1.79 376.11 ± 1.65 319.95 ± 1.51 969.85 ± 1.52
Day 4 9 210.71 ± 1.24 447.90 ± 1.50 301.61 ± 1.28 1060.31 ± 1.26
Day 5 6 212.43 ± 1.32 415.62 ± 1.42 386.61 ± 1.79 1161.49 ± 1.42
Day 6 4 311.99 ± 1.26 632.81 ± 1.24 321.93 ± 1.31 1374.99 ± 1.12
Day 7 3 441.42 ± 1.57 655.10 (1.18) 326.19 ± 2.20 1761.96 ± 1.06
***P < 0.001. †Compared by time to oseltamivir treatment.
Table 4 Multivariate predictors of increase in treatment-related costs
Characteristics β† (% change in
treatment charges)
95%CI (% change) P
Oseltamivir time to treatment (reference group: day 1 of hospitalization)
Day 2 0.209 (23.28) −0.013 to 0.431 (−1.26–53.92) 0.064
≥day 3 0.475 (60.84) 0.282–0.668 (32.59–95.11) <0.0001
Age 0.039 (3.93) 0.012–0.066 (1.16−3.77) 0.006
Presence of pre-existing medical conditions (reference group: absence) 0.717 (104.82) 0.393–1.040 (48.21–183.05) <0.0001
Antibiotics used (reference group none used) 0.412 (50.97) 0.221–0.603 (24.74–82.72) <0.0001
No previous influenza infection in the same year (reference group:
unknown)
0.262 (29.93) 0.069–0.455 (7.11–57.61) 0.001
Diagnosis (reference group: LRTI)
URI −0.092 (–8.75) −0.286 to 0.102 (−24.84 to 10.78) 0.351
Non-respiratory −0.565 (−43.15) −0.840 to −0.289 (−56.84 to −25.13) <0.0001
Clinical attributes at admission
Presence of infiltrate on chest radiographs (reference group: absent) −0.259 (−22.84) −0.489 to −0.029 (−38.71 to −2.86) 0.028
Initial body temperature ≤38.9°C (reference group: >38.9°C) 0.256 (29.24) −0.031 to 0.544 (0.97 to −3.10) 0.080
Normal WBC count (reference group: abnormal) −0.142 (−13.27) −0.323 to 0.038 (0.72 to −27.57) 0.120
Fever duration (reference group: 1–2 days)
3–5 days 0.034 (3.47) −0.142 to 0.210 (0.868 to −13.22) 0.088
6–7 days 0.184 (20.2) −0.010 to 0.379 (0.99 to −1.03) 0.063
Influenza antigen detection test (reference group: test not performed) −0.053 (−5.15) −0.262 to 0.156 (0.77 to −23.05) 0.616
Presence of complications (reference group: absence) −0.034 (−3.31) −0.309 to 0.242 (0.73 to −26.62) 0.139
†Also adjusted for sex, influenza season, presence of signs/symptoms (chills, rales/wheezing, cough, expectoration, rhinorrhea, diarrhea, sore
throat, pharyngitis, rhonchi, and headache). LRTI, lower respiratory tract illness; URI, upper respiratory illness; WBC, white blood cells. The bold
data showed that the value is under 0.05.
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were more likely to be treated with antibiotics in addition to
oseltamivir during hospitalization.
Use of day of admission, that is, the first presentation to
hospital, for calculating time to oseltamivir treatment, rather than
use of onset of symptoms, could be considered a major weakness
in the analysis. There was no statistically significant difference in
the duration from onset of fever to admission between those
treated with oseltamivir within 2 days and those treated ≥day 3
following admission (P = 0.378). The increase in treatment-
related cost seen in this study could be initially suspected to be
due to the longer hospital stay in the patients treated with
oseltamivir ≥day 3 following admission. The lack of statistically
significant difference in the duration of symptomatic illness prior
to admission across the categories of time-to-treatment variable,
however, supports the study aim to assess the economic impact of
time to (oseltamivir) treatment related to hospitalization, not
onset of illness, among Korean children on the economic benefit
of initiating oseltamivir within 2 days of admission, even after 2
days of symptom onset as commonly recommended.
Hiba et al. reported that there were fewer complications after
admission in severe patients hospitalized with 2009 influenza A
(H1N1) who had initiation of oseltamivir within 48 h of symptom
onset, adjusting for disease severity on admission.25 Although
that retrospective study, also based on hospitalized patients, iden-
tified a therapeutic benefit of oseltamivir initiated within the
recommended 2 days of symptom onset, the recommendation
issued by the US Centers for Disease Control and Prevention
(CDC) for the use of antiviral medications in the treatment of
influenza for the 2011–2012 season states that antivirals should
be considered for children with suspected influenza even past 2
days after symptom onset.16 Observational studies noted benefits
of oseltamivir initiated after 48 h of symptom onset with regard
to clinical outcome among patients hospitalized with influenza.
Initiation of oseltamivir treatment within 2 days of onset of
symptoms is often realistically challenging. With these mixed
recommendations, in the present study based on hospital admis-
sion in children hospitalized with influenza, we derived a variable
to reflect the recommended time window for oseltamivir treat-
ment in order to report on the economic benefit of initiating
oseltamivir treatment within 2 days of hospitalization, rather than
within 2 days of onset of symptoms. The objective of this analy-
sis was to assess the impact of time to treatment of oseltamivir on
hospital costs among the hospitalized children treated with
oseltamivir upon first presentation at a health-care facility, rather
than upon onset of symptoms reported with varying consistency
by caregivers, reflecting clinical promptness in true practical
settings.
To assess the difference in treatment cost between the first day
and second day for the onset of oseltamivir treatment, the main
predictor variable, oseltamivir time to treatment, separated out
those who were given oseltamivir on day 1 from those given
treatment on day 2 of admission. There was a >50% increase on
average in treatment-related cost associated with oseltamivir
treatment initiation at ≥3 days of admission, and that as long as
oseltamivir is initiated within 2 days of admission (i.e. first pres-
entation at hospital with respiratory symptoms in the
present study), there will be no significant changes in treatment
cost.
Although we could not identify any study on the economic
benefits of earlier initiation of oseltamivir, other studies have
explored different time points within the recommended 2 day
timeframe of oseltamivir initiation with regard to therapeutic
benefits. Kawai et al. found that oseltamivir initiation at 24 h was
associated with better outcomes in terms of resolution of fever
than initiation at 48 or 72 h.26 In addition, Gillissen and Höffken
showed that illness duration was shortened when oseltamivir was
started within 12 h after onset of symptoms.27 Therapeutic ben-
efits of prompt initiation of oseltamivir were found in both chil-
dren and adults. Heinonen et al. reported a significant reduction
in the resolution of illness if oseltamivir was initiated within 24 h
among children in an outpatient setting,28 and Shijubo et al. noted
a trend of slower fever resolution as initiation of therapy was
delayed (measured at 0, 1–12, 13–24, and 72 h) in a nursing
home setting.29 Given that better clinical outcome is often
associated with lower costs, the present findings seem to be
congruent.
We observed that delayed prescription of oseltamivir was
associated with a longer mean duration of hospitalization.
Although it is impossible to retrospectively determine all the
reasons for oseltamivir prescription delay, the pattern of longer
hospitalization among patients with respiratory symptoms on
admission who were given oseltamivir later during hospitaliza-
tion was consistent with the data in a multicenter study reported
by Aoki et al., showing that earlier oseltamivir treatment reduces
illness duration.21 Considering the previous studies reporting
therapeutic benefits of oseltamivir initiation within 2 days of
symptom onset compared to later in the clinical course,22–24 and
the overall cost-effectiveness of oseltamivir in influenza
treatment,30–32 it is clear that oseltamivir is a first-line treatment
choice for influenza patients and its therapeutic benefit is max-
imized when started as promptly as possible.
In the present study, in which one-third of oseltamivir-treated
patients started treatment ≥day 3 of admission, concurrent anti-
biotic prescription was closely related to initiation of oseltamivir.
A significantly higher rate of antibiotic usage was found among
patients in whom oseltamivir started on ≥day 3 of admission
compared with those with earlier initiation. This may be
explained by the fact that these patients may have had clinical
indications of bacterial pneumonia or secondary infection, so the
decision regarding antibiotic prescription preceded oseltamivir
treatment. In the present study, all 33 patients who were treated
with oseltamivir ≥day 3 of admission had received antibiotics
before oseltamivir prescription, while all 40 patients who
received oseltamivir on admission were prescribed with antibiot-
ics at the same time (n = 33) or after oseltamivir initiation (n = 7).
In clinical practice, children hospitalized with mild conditions
may be less likely to be treated with antibiotics, while those with
more severe findings such as rales/wheezing or chest infiltrate,
indicators of bacterial pneumonia, are often treated with antibi-
otics. The physician decision to prioritize antibiotics due to sus-
picion of bacterial infection may have led to delayed initiation of
oseltamivir.
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The timeliness of oseltamivir treatment may also be influ-
enced by the use of RIDT, given that RIDT is known to be
cost-effective33 and can be used to reduce unnecessary antibiotic
use in patients with viral infection.34,35 Although RIDT was not
significantly associated with increased treatment-associated cost,
the use of RIDT is likely to reflect treatment decisions because
they are ordered at clinician discretion. In the present study, twice
as many people who had oseltamivir earlier, had RIDT compared
to those who had oseltamivir ≥day 3 of admission (P = 0.022).
Among the patients with LRTI who did not undergo RIDT,
54% of the patients (13/24) were given oseltamivir ≥day 3 of
admission while 15% of patients with LRTI who did have RIDT
received oseltamivir ≥day 3 of admission. This shows that
patients who had RIDT were less likely to have a clinical impres-
sion of LRTI. Most of the present cases occurred during the
influenza season. Influenza as a differential diagnosis in hospi-
talized children during the influenza season should be accompa-
nied by prompt use of RIDT for timelier initiation of oseltamivir.
Considering the complexity of treatment decisions related to
initiation of oseltamivir treatment, variation in illness condition
at admission and during the clinical course was an important
confounder. We accordingly used a multivariate model to
adjust for the variability that could have influenced timing of
oseltamivir initiation during hospitalization and by extension, the
relationship of oseltamivir time to treatment and treatment cost.
The data abstraction, however, was limited to the information that
was available on the medical charts due to the retrospective study
design and the small sample size. Other possibly influential con-
founders may be detection of co-infection due to other viral
pathogens during the influenza-related hospitalization and influ-
enza vaccination history, especially given the substantial rate of
national influenza vaccination coverage, which was reported to
be close to 40%.19,20 These additional variables were not available
for abstraction from medical charts during the data collection
phase. Similarly, some other confounding variables that were
unable to be measured in this analysis may possibly explain the
relationship but the observed relationships and the 95%CI make
it unlikely that the present findings are a result of residual con-
founding not controlled for in the models.
Despite these limitations, three tertiary-level hospitals under
the umbrella of KU had a highly uniform standard of patient
management and treatment regimen, so the analysis was not
affected by variability across clinicians and facilities. Moreover,
all study subjects had culture confirmation of influenza virus, in
addition to the use of RIDT at the clinician’s discretion. In Korea,
the predominant circulating strains were A/H3N2 in 2004–2005,
A/H1N1 in 2005–2006, and A/H3N2 in 2006–2007 and there
were no reported oseltamivir-resistant strains of influenza during
the study period of 2004–2007. This approach to diagnosis
ensured uniformity in influenza diagnosis. Based on the medical
chart data over three complete influenza seasons, the present
study provides a realistic illustration of treatment cost according
to oseltamivir time to treatment among Korean children hospi-
talized with laboratory-confirmed influenza.
McNicholl and McNicholl reported that oseltamivir is espe-
cially more effective if initiated within 30 h of symptom onset
and that this criterion is difficult to meet.36 This is evident in the
present study, in which almost one in three oseltamivir-treated
patients was outside the recommended window of oseltamivir
treatment. The present data highlight the benefit among hospital-
ized influenza patients from oseltamivir treatment even if initi-
ated during the hospital stay, possibly outside the recommended
2 day period after symptom onset. Louie et al. also reported
improved survival with prompt initiation of oseltamivir among
children critically ill with influenza, encouraging oseltamivir
treatment for critically ill children at an increased risk of death.37
The present results demonstrate favorable hospitalization-related
outcomes and clear benefits from earlier initiation of oseltamivir,
especially with regard to the economics. Although the present
study is limited by its observational nature, and we cannot defini-
tively conclude that earlier initiation of oseltamivir reduces
treatment-related cost among patients hospitalized with influ-
enza, the current study presents a case for cost savings that is
consistent with previously published known reductions in mor-
bidity, antibiotic use, and hospitalization time.21,26–29 Therefore,
complemented with routine use of quick and sensitive influenza
diagnostics for expeditious clinical decision making, prompt pre-
scription of oseltamivir, even if started outside the recommended
2 day window from onset of symptoms, should be encouraged in
clinical treatment practice in children hospitalized with seasonal
influenza.
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